Open-label extension of PF-07868489 in adults with pulmonary arterial hypertension

Phase 2, open-label, single-arm trial of PF-07868489 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Incidence of related treatment-emergent adverse events and serious adverse events and 3 more. Started Dec 2025; status: completed.